Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Cationic synthetic long peptides-loaded nanogels: An efficient therapeutic vaccine formulation for induction of T-cell responses.

Kordalivand N, Tondini E, Lau CYJ, Vermonden T, Mastrobattista E, Hennink WE, Ossendorp F, Nostrum CFV.

J Control Release. 2019 Oct 28;315:114-125. doi: 10.1016/j.jconrel.2019.10.048. [Epub ahead of print]

2.

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control.

Tondini E, Arakelian T, Oosterhuis K, Camps M, van Duikeren S, Han W, Arens R, Zondag G, van Bergen J, Ossendorp F.

Oncoimmunology. 2019 Sep 2;8(11):1652539. doi: 10.1080/2162402X.2019.1652539. eCollection 2019.

3.

Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles.

Da Silva CG, Camps MGM, Li TMWY, Zerrillo L, Löwik CW, Ossendorp F, Cruz LJ.

Theranostics. 2019 Aug 21;9(22):6485-6500. doi: 10.7150/thno.34429. eCollection 2019.

4.

Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines.

Da Silva CG, Camps MGM, Li TMWY, Chan AB, Ossendorp F, Cruz LJ.

Biomaterials. 2019 Nov;220:119417. doi: 10.1016/j.biomaterials.2019.119417. Epub 2019 Aug 7.

PMID:
31419588
5.

PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.

Beyrend G, van der Gracht E, Yilmaz A, van Duikeren S, Camps M, Höllt T, Vilanova A, van Unen V, Koning F, de Miranda NFCC, Arens R, Ossendorp F.

J Immunother Cancer. 2019 Aug 14;7(1):217. doi: 10.1186/s40425-019-0700-3.

6.

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.

Sow HS, Ren J, Camps M, Ossendorp F, Ten Dijke P.

Cells. 2019 Apr 5;8(4). pii: E320. doi: 10.3390/cells8040320.

7.

Peptides conjugated to 2-alkoxy-8-oxo-adenine as potential synthetic vaccines triggering TLR7.

Gential GPP, Hogervorst TP, Tondini E, van de Graaff MJ, Overkleeft HS, Codée JDC, van der Marel GA, Ossendorp F, Filippov DV.

Bioorg Med Chem Lett. 2019 Jun 1;29(11):1340-1344. doi: 10.1016/j.bmcl.2019.03.048. Epub 2019 Mar 30.

8.

Dual Synthetic Peptide Conjugate Vaccine Simultaneously Triggers TLR2 and NOD2 and Activates Human Dendritic Cells.

Zom GG, Willems MMJHP, Meeuwenoord NJ, Reintjens NRM, Tondini E, Khan S, Overkleeft HS, van der Marel GA, Codee JDC, Ossendorp F, Filippov DV.

Bioconjug Chem. 2019 Apr 17;30(4):1150-1161. doi: 10.1021/acs.bioconjchem.9b00087. Epub 2019 Mar 26.

PMID:
30865430
9.

A Dual-Color Bioluminescence Reporter Mouse for Simultaneous in vivo Imaging of T Cell Localization and Function.

Kleinovink JW, Mezzanotte L, Zambito G, Fransen MF, Cruz LJ, Verbeek JS, Chan A, Ossendorp F, Löwik C.

Front Immunol. 2019 Jan 8;9:3097. doi: 10.3389/fimmu.2018.03097. eCollection 2018.

10.

Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.

Zom GG, Willems MMJHP, Khan S, van der Sluis TC, Kleinovink JW, Camps MGM, van der Marel GA, Filippov DV, Melief CJM, Ossendorp F.

J Immunother Cancer. 2018 Dec 12;6(1):146. doi: 10.1186/s40425-018-0455-2.

11.

Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F.

JCI Insight. 2018 Dec 6;3(23). pii: 124507. doi: 10.1172/jci.insight.124507.

12.

Cytofast: A workflow for visual and quantitative analysis of flow and mass cytometry data to discover immune signatures and correlations.

Beyrend G, Stam K, Höllt T, Ossendorp F, Arens R.

Comput Struct Biotechnol J. 2018 Oct 24;16:435-442. doi: 10.1016/j.csbj.2018.10.004. eCollection 2018.

13.

High FcγR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy.

Benonisson H, Sow HS, Breukel C, Claassens J, Brouwers C, Linssen MM, Fransen MF, Sluijter M, Ossendorp F, van Hall T, Verbeek JS.

J Immunol. 2018 Dec 15;201(12):3741-3749. doi: 10.4049/jimmunol.1800700. Epub 2018 Nov 5.

PMID:
30397036
14.

FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.

Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS.

Int J Cancer. 2019 Jan 15;144(2):345-354. doi: 10.1002/ijc.31899. Epub 2018 Nov 12.

PMID:
30259976
15.

Cationic Liposomes: A Flexible Vaccine Delivery System for Physicochemically Diverse Antigenic Peptides.

Heuts J, Varypataki EM, van der Maaden K, Romeijn S, Drijfhout JW, van Scheltinga AT, Ossendorp F, Jiskoot W.

Pharm Res. 2018 Sep 12;35(11):207. doi: 10.1007/s11095-018-2490-6.

16.

FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines.

Benonisson H, Sow HS, Breukel C, Claassens JWC, Brouwers C, Linssen MM, Redeker A, Fransen MF, van Hall T, Ossendorp F, Arens R, Verbeek S.

Oncotarget. 2018 Jun 29;9(50):29392-29402. doi: 10.18632/oncotarget.25630. eCollection 2018 Jun 29.

17.

Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.

Chung CK, Da Silva CG, Kralisch D, Chan A, Ossendorp F, Cruz LJ.

J Control Release. 2018 Sep 10;285:56-66. doi: 10.1016/j.jconrel.2018.07.011. Epub 2018 Jul 6. Review.

PMID:
30008371
18.

Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.

Hos BJ, Tondini E, van Kasteren SI, Ossendorp F.

Front Immunol. 2018 Apr 26;9:884. doi: 10.3389/fimmu.2018.00884. eCollection 2018. Review.

19.

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System.

Fletcher EAK, van Maren W, Cordfunke R, Dinkelaar J, Codee JDC, van der Marel G, Melief CJM, Ossendorp F, Drijfhout JW, Mangsbo SM.

J Immunol. 2018 Jul 1;201(1):87-97. doi: 10.4049/jimmunol.1700911. Epub 2018 May 11.

20.

Chemical Control over T-Cell Activation in Vivo Using Deprotection of trans-Cyclooctene-Modified Epitopes.

van der Gracht AMF, de Geus MAR, Camps MGM, Ruckwardt TJ, Sarris AJC, Bremmers J, Maurits E, Pawlak JB, Posthoorn MM, Bonger KM, Filippov DV, Overkleeft HS, Robillard MS, Ossendorp F, van Kasteren SI.

ACS Chem Biol. 2018 Jun 15;13(6):1569-1576. doi: 10.1021/acschembio.8b00155. Epub 2018 May 11.

21.

Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.

Ho NI, Camps MGM, de Haas EFE, Ossendorp F.

Eur J Immunol. 2018 Jul;48(7):1164-1173. doi: 10.1002/eji.201747372. Epub 2018 May 17.

22.

A Restricted Role for FcγR in the Regulation of Adaptive Immunity.

Fransen MF, Benonisson H, van Maren WW, Sow HS, Breukel C, Linssen MM, Claassens JWC, Brouwers C, van der Kaa J, Camps M, Kleinovink JW, Vonk KK, van Heiningen S, Klar N, van Beek L, van Harmelen V, Daxinger L, Nandakumar KS, Holmdahl R, Coward C, Lin Q, Hirose S, Salvatori D, van Hall T, van Kooten C, Mastroeni P, Ossendorp F, Verbeek JS.

J Immunol. 2018 Apr 15;200(8):2615-2626. doi: 10.4049/jimmunol.1700429. Epub 2018 Mar 9.

23.

Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses.

Mangsbo SM, Fletcher EAK, van Maren WWC, Redeker A, Cordfunke RA, Dillmann I, Dinkelaar J, Ouchaou K, Codee JDC, van der Marel GA, Hoogerhout P, Melief CJM, Ossendorp F, Drijfhout JW.

Mol Immunol. 2018 Jan;93:115-124. doi: 10.1016/j.molimm.2017.11.004. Epub 2017 Nov 22.

PMID:
29175591
24.

Hollow microneedle-mediated micro-injections of a liposomal HPV E743-63 synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses.

van der Maaden K, Heuts J, Camps M, Pontier M, Terwisscha van Scheltinga A, Jiskoot W, Ossendorp F, Bouwstra J.

J Control Release. 2018 Jan 10;269:347-354. doi: 10.1016/j.jconrel.2017.11.035. Epub 2017 Nov 22.

25.

The potential of multi-compound nanoparticles to bypass drug resistance in cancer.

Da Silva CG, Peters GJ, Ossendorp F, Cruz LJ.

Cancer Chemother Pharmacol. 2017 Nov;80(5):881-894. doi: 10.1007/s00280-017-3427-1. Epub 2017 Sep 8. Review.

26.

Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8+ T Cells.

Kleinovink JW, Fransen MF, Löwik CW, Ossendorp F.

Cancer Immunol Res. 2017 Oct;5(10):832-838. doi: 10.1158/2326-6066.CIR-17-0055. Epub 2017 Aug 29.

27.

PD-L1 immune suppression in cancer: Tumor cells or host cells?

Kleinovink JW, van Hall T, Ossendorp F, Fransen MF.

Oncoimmunology. 2017 May 12;6(7):e1325982. doi: 10.1080/2162402X.2017.1325982. eCollection 2017.

28.

CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy.

Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, Ossendorp F, van der Burg SH, van Hall T.

Cancer Immunol Res. 2017 Aug;5(8):642-653. doi: 10.1158/2326-6066.CIR-16-0334. Epub 2017 Jun 21.

29.

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.

Kleinovink JW, Marijt KA, Schoonderwoerd MJA, van Hall T, Ossendorp F, Fransen MF.

Oncoimmunology. 2017 Feb 21;6(4):e1294299. doi: 10.1080/2162402X.2017.1294299. eCollection 2017.

30.

C1q-Dependent Dendritic Cell Cross-Presentation of In Vivo-Formed Antigen-Antibody Complexes.

Ho NI, Camps MGM, de Haas EFE, Trouw LA, Verbeek JS, Ossendorp F.

J Immunol. 2017 Jun 1;198(11):4235-4243. doi: 10.4049/jimmunol.1602169. Epub 2017 Apr 21.

31.

Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines.

Varypataki EM, Benne N, Bouwstra J, Jiskoot W, Ossendorp F.

Cancer Immunol Res. 2017 Mar;5(3):222-233. doi: 10.1158/2326-6066.CIR-16-0283. Epub 2017 Jan 31.

32.

Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination.

Rad-Malekshahi M, Fransen MF, Krawczyk M, Mansourian M, Bourajjaj M, Chen J, Ossendorp F, Hennink WE, Mastrobattista E, Amidi M.

Mol Pharm. 2017 May 1;14(5):1482-1493. doi: 10.1021/acs.molpharmaceut.6b01003. Epub 2017 Jan 27.

33.

Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds.

Li D, Sun F, Bourajjaj M, Chen Y, Pieters EH, Chen J, van den Dikkenberg JB, Lou B, Camps MG, Ossendorp F, Hennink WE, Vermonden T, van Nostrum CF.

Nanoscale. 2016 Dec 1;8(47):19592-19604.

PMID:
27748778
34.

The Optimization of Bioorthogonal Epitope Ligation within MHC-I Complexes.

Pawlak JB, Hos BJ, van de Graaff MJ, Megantari OA, Meeuwenoord N, Overkleeft HS, Filippov DV, Ossendorp F, van Kasteren SI.

ACS Chem Biol. 2016 Nov 18;11(11):3172-3178. Epub 2016 Oct 10.

PMID:
27704768
35.

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

Zom GG, Welters MJ, Loof NM, Goedemans R, Lougheed S, Valentijn RR, Zandvliet ML, Meeuwenoord NJ, Melief CJ, de Gruijl TD, Van der Marel GA, Filippov DV, Ossendorp F, Van der Burg SH.

Oncotarget. 2016 Oct 11;7(41):67087-67100. doi: 10.18632/oncotarget.11512.

36.

Synthesis and evaluation of fluorescent Pam3Cys peptide conjugates.

Gential GP, Ho NI, Chiodo F, Meeuwenoord N, Ossendorp F, Overkleeft HS, van der Marel GA, Filippov DV.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3641-5. doi: 10.1016/j.bmcl.2016.05.094. Epub 2016 Jun 1.

PMID:
27289322
37.

Glycan modification of antigen alters its intracellular routing in dendritic cells, promoting priming of T cells.

Streng-Ouwehand I, Ho NI, Litjens M, Kalay H, Boks MA, Cornelissen LA, Kaur Singh S, Saeland E, Garcia-Vallejo JJ, Ossendorp FA, Unger WW, van Kooyk Y.

Elife. 2016 Mar 21;5. pii: e11765. doi: 10.7554/eLife.11765.

38.

Vaccines for established cancer: overcoming the challenges posed by immune evasion.

van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ.

Nat Rev Cancer. 2016 Apr;16(4):219-33. doi: 10.1038/nrc.2016.16. Epub 2016 Mar 11. Review.

PMID:
26965076
39.

Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.

Varypataki EM, Silva AL, Barnier-Quer C, Collin N, Ossendorp F, Jiskoot W.

J Control Release. 2016 Mar 28;226:98-106. doi: 10.1016/j.jconrel.2016.02.018. Epub 2016 Feb 11.

PMID:
26876760
40.

Combinatorial prospects of nano-targeted chemoimmunotherapy.

Da Silva CG, Rueda F, Löwik CW, Ossendorp F, Cruz LJ.

Biomaterials. 2016 Mar;83:308-20. doi: 10.1016/j.biomaterials.2016.01.006. Epub 2016 Jan 9. Review.

PMID:
26796043
41.

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.

Doorduijn EM, Sluijter M, Querido BJ, Oliveira CC, Achour A, Ossendorp F, van der Burg SH, van Hall T.

J Clin Invest. 2016 Feb;126(2):784-94. doi: 10.1172/JCI83671. Epub 2016 Jan 19.

42.

PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.

Silva AL, Soema PC, Slütter B, Ossendorp F, Jiskoot W.

Hum Vaccin Immunother. 2016 Apr 2;12(4):1056-69. doi: 10.1080/21645515.2015.1117714. Epub 2016 Jan 11. Review.

43.

Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors.

Kleinovink JW, van Driel PB, Snoeks TJ, Prokopi N, Fransen MF, Cruz LJ, Mezzanotte L, Chan A, Löwik CW, Ossendorp F.

Clin Cancer Res. 2016 Mar 15;22(6):1459-68. doi: 10.1158/1078-0432.CCR-15-0515. Epub 2015 Nov 6.

44.

Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer.

Rahimian S, Fransen MF, Kleinovink JW, Amidi M, Ossendorp F, Hennink WE.

Curr Pharm Des. 2015;21(29):4201-16. Review.

PMID:
26323429
45.

The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion.

Welten SP, Redeker A, Franken KL, Oduro JD, Ossendorp F, Čičin-Šain L, Melief CJ, Aichele P, Arens R.

Elife. 2015 Aug 11;4. doi: 10.7554/eLife.07486.

46.

Therapeutic cancer vaccines.

Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH.

J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. Review.

47.

Lipophilic Muramyl Dipeptide-Antigen Conjugates as Immunostimulating Agents.

Willems MM, Zom GG, Meeuwenoord N, Khan S, Ossendorp F, Overkleeft HS, van der Marel GA, Filippov DV, Codée JD.

ChemMedChem. 2016 Jan 19;11(2):190-8. doi: 10.1002/cmdc.201500196. Epub 2015 Jun 9.

PMID:
26059481
48.

Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.

Rosendahl Huber SK, Camps MG, Jacobi RH, Mouthaan J, van Dijken H, van Beek J, Ossendorp F, de Jonge J.

PLoS One. 2015 Jun 5;10(6):e0127969. doi: 10.1371/journal.pone.0127969. eCollection 2015.

49.

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.

Rahimian S, Fransen MF, Kleinovink JW, Amidi M, Ossendorp F, Hennink WE.

Biomaterials. 2015 Aug;61:33-40. doi: 10.1016/j.biomaterials.2015.04.043. Epub 2015 May 17.

PMID:
25993015
50.

The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells.

Zehner M, Marschall AL, Bos E, Schloetel JG, Kreer C, Fehrenschild D, Limmer A, Ossendorp F, Lang T, Koster AJ, Dübel S, Burgdorf S.

Immunity. 2015 May 19;42(5):850-63. doi: 10.1016/j.immuni.2015.04.008. Epub 2015 May 12.

Supplemental Content

Loading ...
Support Center